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Metabotropic receptors coupled to Gq/G11 family G proteins critically contribute to nervous system functions
by modulating synaptic transmission, often facilitating excitation. We investigated the role of Gq/G11 family G
proteins in the regulation of neuronal excitability in mice that selectively lack the -subunits of Gq and G11,
Gq and G11, respectively, in forebrain principal neurons. Surprisingly, mutant mice exhibited increased
seizure susceptibility, and the activation of neuroprotective mechanisms was impaired. We found that endo-
cannabinoid levels were reduced under both basal and excitotoxic conditions and that increased susceptibility
to kainic acid could be normalized by the enhancement of endocannabinoid levels with an endocannabinoid
reuptake inhibitor, while the competitive cannabinoid type 1 receptor antagonist SR141716A did not cause
further aggravation. These findings indicate that Gq/G11 family G proteins negatively regulate neuronal
excitability in vivo and suggest that impaired endocannabinoid formation in the absence of Gq/G11 contributes
to this phenotype.
Several metabotropic receptors of the central nervous sys-
tem signal through heterotrimeric G proteins of the Gq/G11
family, for example, the metabotropic glutamate receptor sub-
types 1 and 5, the M1 muscarinic acetylcholine receptor, and
the 5-hydroxytryptamine 2 (5-HT2) serotonin receptor. Stimu-
lation of Gq/G11-coupled receptors causes the activation of
phospholipase C- (PLC-) isoforms, leading to inositol phos-
pholipid breakdown, protein kinase C activation, and intracel-
lular calcium mobilization (18). Gq/G11-coupled receptors
have been shown to contribute to the modulation of synaptic
transmission in the hippocampus and cerebellum (1, 23, 25, 33,
37, 46, 48) and are known to facilitate neuronal activation by
opening voltage-dependent cation channels and closing potas-
sium channels (10, 12). In line with this, agonists at the Gq/
G11-coupled metabotropic glutamate receptors or the musca-
rinic acetylcholine receptors promote seizures in vitro and in
vivo (6, 11, 57), while antagonists at these receptors have been
suggested to have anticonvulsive effects (7, 8).
In vitro data, however, indicate that Gq/G11-coupled recep-
tors can also indirectly exert inhibitory effects through the
inhibition of presynaptic calcium channels (22, 45) or the ac-
tivation of the endocannabinoid system. Endocannabinoids
such as anandamide and 2-arachidonoyl glycerol (2-AG) are
lipophilic neuromodulators that are synthesized and released
“on demand” in postsynaptic neurons in response to depolar-
ization-induced calcium influx (14, 34, 50, 69) or activation of
Gq/G11-coupled metabotropic receptors (20, 21, 32, 38, 41, 51,
52, 65). Both transmembrane Ca2 influx and Gq/G11-medi-
ated intracellular Ca2 mobilization enhance anandamide bio-
synthesis via an N-acyltransferase and a specific phospholipase
D-like enzyme (13, 15, 16, 56, 61, 62). In parallel, Gq/G11-
mediated PLC- activation results in the production of diacyl-
glycerol (DAG), which serves as a precursor for 2-AG via
Ca2-sensitive sn-1-DAG lipases (3). PLC-, DAG, and sn-1-
DAG lipase were suggested to be of special importance for the
production of that pool of 2-AG that functions as an endocan-
nabinoid precursor, especially in response to neuronal depo-
larization and in retrograde signaling (9, 16, 44, 56, 62, 63).
Endocannabinoids act mostly via presynaptic cannabinoid type
1 receptors to inhibit neurotransmitter release at inhibitory as
well as excitatory synapses (2, 19, 68), and they were shown to
protect the brain from excitotoxicity and other forms of
neuronal damage (16, 43, 56, 62, 63). However, the relative
weight and function of Gq/G11-mediated signaling in the
regulation of endocannabinoid levels in vivo are unclear. It
is also not clear whether the net effect of Gq/G11 signaling in
vivo is excitatory or inhibitory.
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The two main members of the Gq/G11 family are Gq and
G11, which are almost ubiquitously expressed in the central
nervous system and have highly redundant functions. Since
genetic inactivation of both Gq and G11 causes embryonic
lethality (49), we employed the Cre/loxP system to generate
mice which allow tissue-specific inactivation of Gq in consti-
tutively G11-deficient mice (67). These mice were crossed
with the Camkcre4 mouse line (39), which causes recombina-
tion selectively in principal neurons of the forebrain (40). Fore-
brain-specific Gq/G11 double knockout (fb-Gq/G11-
DKO) mice were viable and fertile and showed normal basic
sensory and motor abilities, but females were unable to raise
normal maternal behavior toward their young (66). We used
fb-Gq/G11-DKO mice to investigate the role of Gq/G11 in
the regulation of neuronal excitability, with a special focus on
the role of Gq/G11 in endocannabinoid synthesis.
MATERIALS AND METHODS
Mice. Genotyping for the gnaqflox allele, the gna11 wild-type and knockout
alleles, and the Cre transgene was described previously (67). The primers used
for detecting the Camkcre4 transgene were 5-TCTCCATTTGCACTCAGGAG
C-3 and 5-AAAACGCCTGGCGATCCCT-G-3. Mice were housed under spe-
cific-pathogen-free conditions, and all animal experiments were performed in
accordance with institutional animal care and use committee regulations. The
genetic background of the mice was predominantly C57BL6/N (fourth-genera-
tion backcross), and nonlittermate C57BL6/N mice or littermates with the
Camkcre4/ gnaqfl/fl gna11wt/wt genotype were used as controls. No significant
differences were observed between the two control groups.
Animal experiments. Kainic acid (KA; Sigma, Deisenhofen, Germany) and pen-
tylenetetrazole (PTZ; Sigma) were dissolved in saline and administered intraperito-
neally (i.p.) at the indicated dosages. N-Piperidino-5-(4-chlorophenyl)-1-(2,4-dichlo-
rophenyl)-4-methyl-3-pyrazolone-carboxamide (SR141716A; Cayman Chemical,
Ann Arbor, MI) and OMDM-2 [(R)-N-oleoyl-(1-hydroxybenzyl)-2-ethanolamine]
(synthesized as previously described [(54]) were dissolved in Tween 80–ethanol–
0.9% saline (1:1:18) and injected i.p. 30 min before KA treatment at the concentra-
tions indicated in the figure legends (for six to eight mice per group). Mice were
monitored for 60 min, and responses were scored every 5 minutes by an observer
blinded to the genotype, as described previously (24). Briefly, responses were scored
as follows: 0, normal behavior; 1, rigid or slowed walking; 2, isolated jerks; 3,
repetitive jerks; 4, forelimb clonus, isolated clonic jerks; 5, repetitive clonic jerks,
mouse on its side with fore- and hindlimb clonus; 6, death. Video and electroen-
cephalography (EEG) monitoring of mice were performed as described previously
(35).
Histology. Mice were deeply anesthetized with pentobarbital, 100 mg/kg of
body weight i.p., and perfused with 4% paraformaldehyde via the left cardiac
ventricle. Their brains were postfixed overnight and then stored in 0.5% para-
formaldehyde at 4°C. Fifty-micrometer vibratome sections were cut and incu-
bated at 4°C with antibodies directed against the following proteins: c-fos protein
(sc-52; Santa Cruz Biotechnology, Santa Cruz, CA; diluted 1:20,000, incubated
for 72 h); zif-268 (Santa Cruz Biotechnology; diluted 1:200, incubated for 72 h);
Gq/G11 (sc-392; Santa Cruz Biotechnology; diluted 1:1,000, incubated for
16 h); GFAP (DAKO, Glostrup, Denmark; diluted 1:500, incubated for 16 h);
NeuN (Chemicon, Temecula, CA; diluted 1:2,000, incubated for 16 h); GAD67
(Chemicon; diluted 1:2,000, incubated for 16 h); calbindin (Chemicon; diluted
1:2,000, incubated for 16 h); calretinin (Chemicon; diluted 1:5,000, incubated for
16 h); and MAP2 (Chemicon; diluted 1:1,000, incubated for 16 h). For staining
we used the Vectastain Elite ABC kits (Vector Labs, Burlingame, CA) and
diaminobenzidine (Vector Labs). Nissl staining was performed according to
standard protocols. Timm staining was performed as described previously (5).
Sections were photographed using a Leica DMLB microscope and a Leica
DC300F camera (Leica, Bensheim, Germany). The numbers of c-fos- or
zif-268-positive cells were counted manually or with a CellExplorer 2003
program (BioSciTec, Germany) by investigators blinded to genotype and
treatment. For each group of mice, two sections from each of four animals
were analyzed.
Endocannabinoid levels. Mice (six to eight per group) were sacrificed 20 min
after injection of 20 mg/kg kainate, and hippocampi were rapidly dissected,
snap-frozen, and stored at 80°C. Endocannabinoids were extracted, and their
levels were measured by isotope dilution liquid chromatography-mass spectrom-
etry as described previously (40).
Electrophysiology. Hippocampal sections from 3- to 5-week-old forebrain-
specific Gaq/Ga11 double knockout mice and wild-type mice were prepared as
described previously (53). Recordings were made from CA1 pyramidal neurons
in slices with patch pipettes pulled from 1.5-mm-outer-diameter, thick-walled
glass tubing (1511-M; Friedrich & Dimmock). Whole-cell tight seals (2 G)
were made on the soma under visual control with a 40 water immersion lens.
Cells were identified as pyramidal neurons by using both electrical and anatom-
ical criteria. Capacitance was fully compensated for by a patch clamp amplifier
(EPC-9; HEKA). The holding potential was 60 or 70 mV. The range of series
resistances we accepted for recordings was 10 to 15 M. Bipolar stimulation
electrodes constructed from thin tungsten wires (50-	m outer diameter) were
placed on the stratum radiatum in the CA2 to CA3 pyramidal regions. For
inhibitory postsynaptic current (IPSC) recording, the pipette solution contained
130 mM CsCl, 5 mM KCl, 5 mM NaCl, 10 mM HEPES, 0.6 mM EGTA, 4 mM
Mg-ATP, and 0.3 mM GTP, with the pH adjusted to 7.3 with NaOH. A non-N-
methyl-D-aspartate (non-NMDA) receptor antagonist (6-cyano-7-nitroquinoxal-
line-2,3-dione, 20 	M) and an NMDA antagonist (DL-2-amino-5-phosphonova-
leric acid, 50 	M) were always added to the perfusing solution. The CB1 receptor
agonist WIN55,212-2 {R-()-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyr-
rolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate} was applied
at 5 mM. Single traces are averaged from five consecutive IPSCs acquired before and
at the end of the WIN55,212-2 application. Chemicals were obtained from Sigma-
Aldrich Co.
Statistics. All data except electrophysiological data are presented as means 

standard error of the means; electrophysiological data are presented as means 

standard deviations. Data were analyzed by analysis of variance followed by
Bonferroni’s post-hoc test. Statistical analysis was performed by repeated-mea-
sure two-way analysis of variance for the factors “treatment” and “genotype” and
the interaction “treatment/genotype.”
FIG. 1. Spontaneous epileptic seizures in fb-Gq/G11-DKO mice.
(A) Percentages of fb-Gq/G11-DKO mice (KO; n  30) (triangles)
and control mice (WT; n  30) (squares) with epileptic seizures.
(B) Cortical EEGs from an fb-Gq/G11-DKO mouse during a myo-
clonic seizure (DKO) and from a wild-type mouse without seizures
(WT). (C) Percentages of postnatal survival of fb-Gq/G11-DKO
mice (KO; n  30) (triangles) and control mice (WT; n  30)
(squares).
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Starting at the age of about 3 months, fb-Gq/G11-DKO
mice showed spontaneous epileptic seizures, and both the fre-
quency of seizures in each animal and the number of affected
animals increased with age (Fig. 1A). The most frequent forms
of seizure were mild myoclonic seizures, and combined EEG
and video monitoring of mutant mice showed a series of rhyth-
mic spikes (0.2 
 0.03 Hz; 45 s, 7-min duration; 0 to 5 times a
day) (Fig. 1B, left panel) concomitant with myocloni of the
body. Such episodes were not observed in wild-type animals
(Fig. 1B, right panel). Some animals also experienced clonic-
tonic seizures, leading to an age-dependent reduction of sur-
vival (Fig. 1C).
Histological and immunohistochemical analyses of mice
younger than 3 months did not show abnormalities (data not
shown). However, older mice, especially those with symptomatic
epilepsy, showed neuronal degeneration and reactive gliosis in the
hippocampal CA1 region, indicative of temporal lobe epilepsy
(Fig. 2). In contrast to other models of temporal lobe epilepsy, we
did not observe mossy fibers sprouting in sections visualized by
Timm staining (data not shown).
To investigate whether abnormalities in neuronal excitability
are present before the onset of spontaneous seizures, we stud-
ied the effects of chemical convulsants in 6- to 10-week-old
fb-Gq/G11-DKO mice in vivo. We found that the application
of the glutamate receptor agonist KA or the gamma aminobu-
tyric acid type A (GABAA) receptor antagonist PTZ induced
stronger seizures in fb-Gq/G11-DKO mice than in wild-type
mice (Fig. 3A and C) and that mutant mice exhibited seizures
at dosages that were already subconvulsive in wild-type mice
(Fig. 3A). Latency to seizure onset was decreased in fb-Gq/
G11-DKO mice (Fig. 3B and D), while seizure-associated
lethality was strongly increased (data not shown). Mice with a
single deficiency in Gq or G11 showed mildly increased sei-
zure susceptibility when challenged with kainic acid (see Fig.
S1 in the supplemental material).
KA-induced seizures have been shown to be accompanied by
enhanced expression of immediate early genes like c-fos, fosB,
or zif-268 in the hippocampi of wild-type mice (30), and espe-
cially c-fos expression appears to be critically involved in the
protection against KA-induced excitotoxicity (40, 70). To test
whether the impaired activation of potentially neuroprotective
pathways may contribute to increased seizure susceptibility in
fb-Gq/G11-DKO mice, we investigated the expression of c-
fos and zif-268 proteins in untreated and KA-treated wild-type
and mutant mice (Fig. 4). Compared to the upregulation in
wild-type mice, the KA-induced upregulation of both proteins
was almost abrogated in hippocampi from fb-Gq/G11-DKO
mice (Fig. 4), suggesting that neuroprotective mechanisms are
impaired in these mice.
Since increased excitability and impaired immediate early
gene activation are also observed in mice lacking endocannabi-
noid CB1 receptors in principal forebrain neurons and since
the Gq/G11 G proteins have been involved in endocannabinoid
synthesis, we determined the levels of anandamide and 2-AG
in the hippocampi of wild-type and fb-Gq/G11-deficient
mice (Fig. 5). Under basal conditions, anandamide levels were
significantly lower in mutant mice than in controls (Fig. 5A),
while 2-AG levels did not differ significantly (Fig. 5B). The
chemical convulsant KA enhanced both anandamide and
2-AG levels in control mice (Fig. 5A and B). Interestingly, KA
treatment still increased anandamide levels in fb-Gq/G11-
DKO mice but failed to induce 2-AG synthesis (Fig. 5A and
B). In mice with a single deficiency in Gq or G11, KA-
induced synthesis of 2-AG was also impaired, but the reduc-
tion was less prominent than in fb-Gq/G11-deficient mice
(see Fig. S1 in the supplemental material). These data in-
dicate that basal hippocampal levels of anandamide, but not
of 2-AG, are under tonic control of the Gq/G11-mediated
signaling pathway. In contrast, Gq/G11-mediated signaling is
necessary for KA-induced formation of 2-AG but not of
anandamide.
To further test whether the reduced formation of endocan-
FIG. 2. Histological changes in hippocampi of fb-Gq/G11-DKO
mice. Hippocampal sections from 8-month-old control mice (upper
row) and fb-Gq/G11-DKO mice (lower row) stained with antibodies
against Gq/G11, NeuN, and GFAP proteins.
FIG. 3. Increased sensitivities toward chemical convulsants of 6- to
10-week-old fb-Gq/G11-DKO mice compared with those of control
mice. Seizure scores (A and C) and latency periods (B and D) to first
clonic-tonic (ct) convulsions after intraperitoneal application of kainic
acid (A and B) or PTZ (C and D) in control and fb-Gq/G11-DKO
mice (five to six mice per group). *, P  0.05; **, P  0.01; ***, P 
0.001. Seizures were scored as described previously (28).
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nabinoids in the absence of Gaq/G11 is involved in abnormal
neuronal excitability and impaired neuroprotection, we pre-
treated mice with the CB1 receptor antagonist SR141716A. As
expected, SR141716A strongly aggravated KA-induced sei-
zures in wild-type mice (Fig. 6A). However, in fb-Gq/G11-
DKO mice, a blockade of CB1 receptors did not further ag-
gravate KA-induced seizures (Fig. 6A). In this experiment, KA
was administered at the reduced dosage of 10 mg/kg to detect
the potential aggravation of seizure intensity in fb-Gq/G11-
DKO mice as well, which have per se higher seizure scores
than wild-type mice (see Fig. 3). Since SR141716A is a com-
petitive antagonist at the CB1 endocannabinoid receptor,
the lack of SR141716A aggravation of KA-induced seizures
in fb-Gq/G11-DKO mice supports our finding that endog-
enous levels of endocannabinoids are significantly decreased
in fb-Gq/G11-DKO mice, at least at those synapses in-
volved in CB1-mediated neuroprotection. To enhance endo-
cannabinoid levels selectively at sites of physiological pro-
duction, we treated mice with the endocannabinoid
reuptake inhibitor OMDM-2 (54). OMDM-2 caused a slight
but nonsignificant amelioration of seizures induced by 30
mg/kg KA in wild-type mice but a strong amelioration in
fb-Gq/G11-DKO mice (Fig. 6B), suggesting that endocan-
nabinoid-mediated effects are basically functional in mutant
mice. To further substantiate this notion, we investigated
cannabinoid-mediated retrograde inhibition of synaptic
transmission by electrophysiological means. In both the
FIG. 4. Kainate-induced upregulation of immediate early genes is impaired in fb-Gq/G11-DKO mice. (A and B) Staining with antibodies against
c-fos (A) and zif-268 (B) proteins in the hippocampi of control and fb-Gq/G11-DKO mice 45 min after intraperitoneal injection of saline or 20
mg/kg KA. (C and D) Statistical evaluation of the number of c-fos-positive (C) or zif-268-positive (D) cells in hippocampal regions CA1 and CA3
and the dentate gyrus (DG) (four mice per group). Black bars, control mice; white bars, fb-Gq/G11-DKO mice; ***, P  0.0001 versus kainate
wild-type mice.
FIG. 5. Endocannabinoid levels in hippocampi of fb-Gq/G11-
DKO mice. (A and B) Anandamide (AEA) (A) and 2-AG (B) levels
were determined by isotope dilution liquid chromatography-mass spec-
trometry in hippocampi from control and fb-Gq/G11-DKO mice
after intraperitoneal application of saline or 20 mg/kg KA (six to eight
mice per group). **, P  0.01; ***, P  0.001 versus saline in wild-type
mice; §§§, P  0.001 versus saline in fb-Gq/G11-DKO mice; ##,
P  0.01 versus KA in wild-type mice.
FIG. 6. Pharmacological manipulation of the endocannabinoid sys-
tem in wild-type and fb-Gq/G11-DKO mice. (A and B) Effect of the
competitive CB1 antagonist SR141716A (A) and the endocannabinoid
reuptake inhibitor OMDM-2 (B) on kainic acid-induced seizures. The
fb-Gq/G11-DKO (KO) and control (WT) mice received saline (Sal),
3 mg/kg SR141716A (SR), or 5 mg/kg OMDM-2 (OM) intraperitone-
ally 30 min before the application of kainic acid (at 10 [A] or 30 [B]
mg/kg KA; six to eight mice per group). *, P  0.05, saline-treated
versus OMDM-2-treated fb-Gq/G11-DKO mice; ***, P  0.001,
saline-treated versus SR-treated wild-type mice.
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wild-type and the mutant hippocampal slices, the applica-
tion of the CB1 receptor agonist WIN55,212-2 caused a
significant reduction in the amplitude of IPSCs in CA1 hip-
pocampal neurons (see Fig. S2 in the supplemental mate-
rial). Taken together, both pharmacological and electro-
physiological data indicate that endocannabinoid-mediated
protective mechanisms are basically intact in fb-Gq/G11-
DKO mice but that endogenous cannabinoid production is
impaired.
DISCUSSION
In this study we have shown that genetic inactivation of the
Gq/G11-mediated signaling pathway in principal forebrain neu-
rons results in increased neuronal excitability. This finding was
unexpected since the modulatory effects of Gq/G11-mediated
signaling are believed to facilitate rather than dampen neuro-
nal activity. However, increased seizure susceptibility was also
found in mice lacking PLC-1 (31), the inositol 1,4,5-trisphos-
phate receptor (42), or the Gq/G11-coupled 5-HT2c receptor
(60), suggesting that the Gq/G11-mediated signaling pathway
indeed exerts important inhibitory effects.
Only a few Gq/G11-mediated effects that might promote
neuronal inhibition have been described. Gq/G11-coupled
receptors are present on hippocampal interneurons (26, 64),
and impaired activation of these cells might shift the balance
between excitation and inhibition. However, since Cre-me-
diated recombination in the Camkcre4 mouse line is re-
stricted to principal neurons (40), this model obviously does
not apply here. Some Gq/G11-coupled receptors, e.g., the M1
acetylcholine receptor, have been suggested to negatively
regulate N-type calcium channels through a breakdown of
membrane phosphatidylinositol 4,5-biphosphate (29) and
thereby might contribute to inhibition. However, given the
fact that a majority of inhibitory presynaptic G protein-
coupled receptors, such as adenosine A1, 2 adrenergic 	
and  opioid, and GABAB receptors, signal through Gi/o
family G proteins (17, 45), the contribution of Gq/G11-cou-
pled receptors to calcium channel regulation seems to be
rather small. Also, the endocannabinoid CB1 receptor is
known to mediate its presynaptic inhibitory effects through
Gi/o family G proteins (27, 28, 47, 55). It was recently re-
ported that the synthetic CB1 agonist WIN55,212-2 induces
a calcium response in CB1-transfected HEK293 cells in a
Gq/G11-dependent manner; however, natural CB1 agonists
such as 9-tetrahydrocannabinol, 2-AG, and anandamide
analogues did not elicit such responses (36).
Though not directly coupled to CB1, the Gq/G11-mediated
signaling pathway was suggested to contribute to endocannabi-
noid functions through its role in endocannabinoid synthesis.
We found that hippocampal levels of anandamide, but not of
2-AG, are reduced in the absence of Gq/G11, indicating that
anandamide formation is under the tonic control of receptors
coupled to these G proteins, while 2-AG formation is not.
Muscarinic and purinergic receptors are among the G protein-
coupled receptors that might contribute to basal anandamide
levels as they are able to induce anandamide formation in the
absence of extracellular Ca2 as well (61). On the other hand,
in the formation of basal 2-AG levels as previously described,
PLC--independent biosynthetic routes (4, 59) seem to pre-
dominate.
In contrast to basal 2-AG production, Gq/G11-mediated sig-
naling is indispensable for hippocampal 2-AG formation fol-
lowing KA application, and this might be due to the fact that
DAG, a fundamental precursor of that pool of 2-AG that acts
as an endocannabinoid (13, 15, 70), is mostly formed in depo-
larized neurons following the activation of PLC- (58). In
contrast to 2-AG formation in response to KA, Gq and G11 are
not necessary for KA-induced anandamide formation. This
observation supports the concept that anandamide can be pro-
duced in response to either metabotropic (61) or ionotropic
(15) receptor stimulation alone, provided that the intracellular
Ca2 concentration is increased in order to induce the activa-
tion of Ca2-sensitive biosynthesizing enzymes and the subse-
quent processing of non-PLC--derived biosynthetic precur-
sors (54). With respect to the differential role of the two
endocannabinoids in control of excitability, it is important to
note that in wild-type mice, KA-induced 2-AG concentrations
are at least 50-fold higher than the anandamide concentra-
tions, and the loss of KA stimulation therefore results in much
lower total endocannabinoid concentrations in fb-Gq/G11-
DKO mice than in wild-type mice (a net increase of 0.06 plus
3.35 or 3.41 nmol/g tissue in wild-type mice compared to a net
decrease of 0.12 to 0.3 or 0.18 nmol/g tissue in fb-Gq/G11-
DKO mice) (Fig. 5).
The phenotype of CB1 receptor-deficient mice resembles
that of fb-Gq/G11-DKO mice in that both mouse strains
have increased seizure susceptibilities in response to KA
and inabilities to induce expression of immediate early
genes encoding the c-fos and zif-268 transcription factors,
which are believed to counteract excitotoxic damage (40,
70). This supports the hypothesis that impaired endocan-
nabinoid-mediated retrograde signaling underlies increased
neuronal excitability in fb-Gq/G11-DKO mice. However,
forebrain-specific CB1-deficient mice seem to be less prone
to spontaneous epilepsy, although seizures have been ob-
served in these animals, especially during the stress of han-
dling (B. Lutz, personal communication). This phenotypic
difference might be explained by the presence of non-CB1
(13, 16, 19, 56) receptors on hippocampal principal neurons,
which contributes to endocannabinoid-mediated neuropro-
tection. In addition, defects in other Gq/G11-mediated pro-
cesses which occur independently of endocannabinoids and
which under normal conditions decrease neuronal activity,
like the above-mentioned negative regulation of N-type
Ca2 channels, may contribute to the more-severe pheno-
type observed in fb-Gq/G11-DKO mice.
Taken together, our data suggest that the Gq/G11-mediated
signaling pathway is critically involved in endocannabinoid syn-
thesis under both basal and excitotoxic conditions. The phe-
notypical similarities between forebrain-specific CB1-deficient
mice and pharmacological in vivo data indicate that impaired
endocannabinoid formation is associated with increased sei-
zure susceptibility and impaired neuroprotection. However,
defective endocannabinoid synthesis may not account exclu-
sively for the increased neuronal excitation in the absence of
Gq/G11, and other Gq/G11-mediated inhibitory mechanisms
may contribute to the phenotype.
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